# R-07 — Musely The Private Cream — Desire · Bliss · Delight · Tender

Hydroquinone up to 12%, marketed for the underarm, groin, genital and perianal areas. Scrotal skin absorbs roughly forty-two times what forearm skin does. One concentration is being sold across sites that differ that much, and nothing on the page adjusts for it.

- **Canonical:** https://www.30plusskin.care/reviews/musely-the-private-cream
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 12 / REV. 2026.08
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## Verdict

- **Stance:** AVOID — We would not buy this, and we say why.
- **Weighted score:** 36/100 across 75% of the scoring model
- **Category:** PRESCRIPTION COMPOUNDED / INTIMATE HYPERPIGMENTATION
- **Price:** $36 — PER MONTH · 2-MONTH MINIMUM
- **Container size:** NOT PUBLISHED
- **Prescription:** yes
- **Compounded:** yes
- **Assessment basis:** DESK REVIEW
- **Last updated:** 2026-07-24
- **Manufacturer page:** https://www.musely.com/privatecream

This is the first product in the register we are advising against, and we want to be precise about why, because two of the four formulas behind this page are perfectly defensible. Tender is tranexamic acid 6% with niacinamide and no hydroquinone at all. Delight is hydroquinone 3%, below the threshold the ochronosis literature flags. Either of those, on intertriginous skin, with a prescriber paying attention, would be a reasonable product.

The objection is to what this page can dispense. Desire is hydroquinone 12% — the highest concentration in Musely's entire range — and the marketed application sites include the genitals and the perianal area. Regional absorption is not a rounding error here. In the foundational human data, scrotal skin absorbed roughly forty-two times as much as forearm skin; the axilla absorbed four to seven times as much. These are not adjacent numbers, and the page offers a single product across all of them with no site-specific instruction we could find.

Layered on top: intertriginous skin is naturally occluded, and occlusion is the standard technique for deliberately increasing topical penetration. So the sites in question combine the thinnest, most permeable skin on the body with a built-in occlusive dressing, and the product may arrive at three times the conventional prescription strength.

There is also a clinical point the page does not raise at all. Darkening of the groin and underarms is the classic presentation of acanthosis nigricans, which is most commonly associated with obesity and insulin resistance. A service that treats that appearance cosmetically without asking why it is there can bleach a diagnostic sign off someone who needed a blood test. That is a screening question, not a formulation problem, and it would cost one line to add.

## Actives, as published

| Active | Concentration | Role | Benchmark | Assessment | Flagged |
| --- | --- | --- | --- | --- | --- |
| Hydroquinone | 3% · 6% · 12% by formula | Tyrosinase inhibitor | 4% conventional prescription strength, established on facial and limb skin | The concentration ladder is fine in the abstract. What is missing is any adjustment for site: the 4% benchmark comes from studies on skin that absorbs a fraction of what genital and axillary skin does, so the effective delivered dose here is far higher than the number implies. | yes |
| Tranexamic Acid | 6% (Tender only) | Interrupts the plasminogen pathway upstream of tyrosinase | 3%–10% topically in the pigmentation literature | A sensible dose and by some distance the best choice on this page. It avoids the ochronosis question entirely and is far better suited to high-absorption skin. | no |
| Niacinamide | 2% | Inhibits melanosome transfer, anti-inflammatory, barrier support | 2%–5% evidenced; 4% used elsewhere in this same range | At the bottom of the useful range, and notably half the 4% Musely uses in its acne and anti-ageing creams. On skin this reactive, the barrier-supporting active is the one you would want more of, not less. | yes |

## Formula variants

The product page names three ingredients as though there is one cream. There are four formulas, three of which contain hydroquinone at 3%, 6% or 12%, and one of which contains none. Which you receive is decided for you, and the page does not tell you the range exists.

| Variant | For whom | Actives | Assessment |
| --- | --- | --- | --- |
| TENDER | Hydroquinone-free option | Tranexamic Acid 6%; Niacinamide 2% | The one we would accept. Topical tranexamic acid has a reasonable evidence base for pigmentation, carries none of the ochronosis question, and is far more forgiving on skin that absorbs like this. This should be the default here, not the alternative. |
| DELIGHT | Lowest hydroquinone tier | Hydroquinone 3%; Niacinamide 2% | Below the 4% threshold the ochronosis literature associates with elevated risk, and close to conventional prescription strength. Defensible on intertriginous skin with supervision, though still worth site-specific instruction. |
| BLISS | Middle hydroquinone tier | Hydroquinone 6% (flagged); Niacinamide 2% | Above the conventional 4% prescription strength, on skin that absorbs several times more than the sites that figure was established on. Needs an explicit rationale and a stop date, neither of which is published. |
| DESIRE | Highest tier | Hydroquinone 12% (flagged); Niacinamide 2% | Three times the conventional prescription strength, on the most permeable skin on the body, under natural occlusion, daily, on an open-ended subscription. This is the formula the verdict is about. |

## Scoring

| Criterion | Weight | Score | Note |
| --- | --- | --- | --- |
| EVIDENCE FOR THE ACTIVE | 30% | 40/100 | Hydroquinone and tranexamic acid both have real evidence for pigmentation — but that evidence was generated on facial and limb skin. Regional absorption differs by more than an order of magnitude at the sites this product is marketed for, so the dose-response relationship the trials established does not transfer. We could find no trial base for hydroquinone at these concentrations on genital or perianal skin. |
| FORMULATION INTEGRITY | 20% | 45/100 | Genuine credit for two things: a proper 3-6-12 concentration ladder, and a hydroquinone-free tranexamic acid option. Against that, a single product is sold across anatomical sites spanning roughly a fortyfold absorption range with no site-specific dosing, and niacinamide is dropped to 2% when the same company uses 4% elsewhere. |
| DISCLOSURE | 15% | 15/100 | No concentrations on the page. Four formulas presented as a single three-ingredient list. No indication that a hydroquinone-free option exists. No site-specific guidance. And no mention that darkening at these exact sites can be a metabolic sign rather than a cosmetic one. |
| TOLERANCE IN USE | 15% | not scorable | Not assessed, and this is the criterion we would most want panel data on. Intertriginous skin is thin, occluded and prone to irritant reactions, and irritation on these sites is both more uncomfortable and more likely to cause post-inflammatory darkening. |
| TEXTURE & WEAR | 10% | not scorable | Not assessed. Requires the product in hand over the full trial window. |
| COST PER APPLICATION | 10% | 35/100 | $36 a month with no published container size, for an indefinite subscription treating a condition that is, for many people, normal anatomy. The price is not the problem; the open-ended structure on these sites is. |

_A criterion that cannot be assessed from published information is not guessed at. Its weight is removed from the denominator, and the coverage figure above says how much of the model survived._

## Strengths

- A hydroquinone-free option exists — Tender, with tranexamic acid 6% — and it is a genuinely sensible formulation for this application.
- There is a real concentration ladder at 3%, 6% and 12% rather than a single strength.
- The page correctly states the product is not formulated for facial use.
- Prescription gating with a prescriber is the right architecture for hydroquinone at any strength.
- Niacinamide is a sound choice of supporting active for reactive, occluded skin.

## Weaknesses

- Hydroquinone up to 12% marketed for genital and perianal application, where absorption is roughly fortyfold that of forearm skin.
- No site-specific dosing guidance across sites that differ enormously in permeability.
- Intertriginous skin is naturally occluded, which further increases penetration.
- No mention that groin and underarm darkening can be acanthosis nigricans, a marker of insulin resistance.
- Four formulas presented on the page as one three-ingredient product.
- No concentrations published, and no indication a hydroquinone-free option exists.
- Niacinamide at 2%, half the concentration used in the company's own face products.
- Open-ended subscription for hydroquinone above 4%, which the ochronosis literature associates with prolonged use.
- The 71% figure is an uncontrolled, unblinded, self-reported survey.

## Suits

- Someone with genuine post-inflammatory darkening from friction, waxing or a healed skin condition, who has had a metabolic cause excluded first.
- Someone who has specifically asked for and been prescribed the Tender formula.
- Someone treating the inner thigh or underarm rather than genital or perianal skin, with a defined stop date.
- Someone whose prescriber has given explicit, site-specific instructions on quantity, frequency and duration.

## Avoid if

- You are being sent the Desire formula for genital or perianal application. Ask for a different formula or a different service.
- The darkening appeared gradually across the groin, underarms and neck together — get insulin resistance excluded before treating the appearance.
- You are pregnant or breastfeeding.
- You have not been given site-specific instructions on how much to apply, where, and for how long.
- You are treating what is, on examination, normal anatomical pigmentation. Genital and perianal skin is naturally darker than surrounding skin in most people.
- You want to use it indefinitely. Hydroquinone above 4% is not an indefinite product anywhere on the body, least of all here.

## The full assessment

### What it is

The Private Cream is a compounded prescription depigmenting cream marketed for hyperpigmentation of the underarms, groin, inner thigh, genital and perianal areas. It is $36 a month starting with a two-month supply, and the page names three ingredients: hydroquinone, niacinamide and tranexamic acid.

There are in fact four separate formulas. Desire is hydroquinone 12% with niacinamide 2%. Bliss is hydroquinone 6%. Delight is hydroquinone 3%. Tender contains no hydroquinone at all — tranexamic acid 6% with niacinamide 2%. None of that appears on the page.

We should say plainly at the outset that wanting to treat this is not something we have any interest in editorialising about. Post-inflammatory darkening from friction, hair removal or a healed skin condition is real, common and treatable. What we are assessing is whether the product as sold is a safe way to do it.

**RECORD**

| Field | Value |
| --- | --- |
| BRAND | MUSELY |
| PRODUCT | THE PRIVATE CREAM |
| CLASS | COMPOUNDED PRESCRIPTION TOPICAL |
| MARKETED SITES | UNDERARM · GROIN · INNER THIGH · GENITAL · PERIANAL |
| FORMULAS | 4 — HQ 3% / 6% / 12%, OR TXA 6% |
| PRICE | $36 / MONTH · 2-MONTH MINIMUM |
| FILL VOLUME | NOT PUBLISHED |
| SITE-SPECIFIC DOSING | NONE FOUND |

### The finding: a percentage is not a dose here

Every concentration benchmark we have used across this register — 4% hydroquinone as the conventional prescription strength, the 4% threshold in the ochronosis literature — comes from studies conducted on facial and limb skin. Those benchmarks carry an unstated assumption: that the skin receiving the product absorbs like ordinary skin.

At the sites this product is marketed for, that assumption does not hold, and it does not fail by a little.

**FIG. 1 — REGIONAL PERCUTANEOUS ABSORPTION, RELATIVE TO FOREARM** — From the foundational human regional-variation data. The forearm is the reference at 1×. These are the sites this single product is sold for.

| Item | Value (× FOREARM) | Note |
| --- | --- | --- |
| FOREARM — THE REFERENCE SITE | 1 | Where the benchmarks were established |
| AXILLA (UNDERARM) | 6 | Four to sevenfold, and naturally occluded |
| SCROTUM | 42 | Almost total absorption |

_Scale maximum: 42× FOREARM._

A 12% hydroquinone applied to scrotal skin is not a 12% hydroquinone in any sense the trials would recognise. The delivered dose is in a different regime altogether, and there is no published trial base establishing what that regime does over months of daily use.

> **OCCLUSION MAKES IT WORSE, NOT BETTER** — Intertriginous sites — groin, underarm, gluteal cleft — are skin folded against skin. That is a natural occlusive dressing, and occlusion is the standard technique for deliberately increasing the penetration of a topical drug. So the most permeable skin on the body is also, at these sites, permanently under an occlusive layer.

The practical consequence is that the same tube, at the same concentration, delivers wildly different doses depending on where it lands. A quantity that is unremarkable on the inner thigh is a substantially larger exposure in the groin and larger again on genital skin. We could find no site-specific guidance addressing this anywhere on the product page.

### The thing that should be screened for first

Darkened, velvety, thickened skin appearing symmetrically in the axillae, the groin and often the neck has a name. It is acanthosis nigricans, and it is most commonly associated with obesity and insulin resistance. It is a recognised clinical marker of metabolic disturbance, including type 2 diabetes and metabolic syndrome.

The anatomical sites this product is marketed for are precisely the sites where acanthosis nigricans presents.

> **WHAT THIS RISKS** — A service that treats darkening at the axilla and groin as a cosmetic complaint, without asking whether it appeared gradually and symmetrically, can lighten a visible sign of undiagnosed insulin resistance. The patient gets a cosmetic result and keeps the underlying condition. This is not a hypothetical failure mode; it is the ordinary consequence of treating a sign without asking what it signifies.

We are not asserting that Musely's intake fails to ask. We cannot see it. What we can see is that nothing on the public page raises it, and that the fix is trivial: a single screening question about onset, symmetry and whether the neck is also involved, and a referral pathway when the answer suggests a metabolic cause. For a company that has built a telehealth intake anyway, this is a small addition with a large safety return.

### Tender is the formula this page should lead with

It would be easy to write this review as though the whole page were indefensible, and that would be inaccurate. Tender — tranexamic acid 6% with niacinamide 2%, and no hydroquinone — is a well-judged formulation for this application.

Topical tranexamic acid has a reasonable evidence base for pigmentation, works upstream of tyrosinase rather than on it, and carries none of the ochronosis question that makes hydroquinone concentration such a live issue. On skin that absorbs like this, choosing the active with the more forgiving safety profile is straightforwardly the right call.

That it exists is to the company's credit. That a prospective buyer has no way of knowing it exists — because the page lists three ingredients as though they arrive together in one tube — is the problem. If we were redesigning this page, Tender would be the default, hydroquinone would be the escalation, and the reason would be printed next to both.

### One more note on what is being treated

Genital and perianal skin is more pigmented than surrounding skin in most people. That is baseline anatomy, not a condition, and it varies enormously between individuals and skin tones.

We raise it once, without moralising, for a practical reason: a product sold on an open-ended monthly subscription for something that may not be a pathology has no natural endpoint. Post-inflammatory darkening from waxing fades and treatment can stop. Normal anatomical pigmentation does not resolve, because there is nothing to resolve, and the subscription simply continues.

### The 71% figure

Seventy-one percent of patients reported visible improvement by day 30, from 22,740 patients logging results at days 7, 30 and 60. Self-reported, uncontrolled, unblinded, assessed by the purchaser. The grade is the same as every other figure in this range and so is the reasoning.

**GRADING THE CITED EVIDENCE**

| Field | Value |
| --- | --- |
| DESIGN | SELF-REPORTED, UNCONTROLLED |
| N | 22,740 |
| CONTROL ARM | NONE STATED |
| BLINDING | NONE |
| ASSESSOR | THE PURCHASER |
| SITE STRATIFICATION | NONE — DESPITE ~42× ABSORPTION RANGE |
| OUR GRADE | C — OPEN-LABEL |

The site stratification line is the one that matters here. A single response rate pooled across the underarm and the genital area is averaging across a fortyfold difference in delivered dose. Whatever that number describes, it is not one treatment.

### If you proceed anyway

- Ask which of the four formulas you have been prescribed, by name and concentration. Do not accept a list of ingredients as an answer.
- Ask specifically about Tender. If hydroquinone is being prescribed instead, ask why it is preferred for this site.
- If the darkening came on gradually and affects your underarms, groin and neck together, ask for a fasting glucose and HbA1c before treating it.
- Get site-specific instructions: how much, where exactly, how often. Do not extrapolate a face-sized dose to this application.
- Do not apply to genital or perianal skin without explicitly confirming the product is intended for that site at that concentration.
- Agree a stop date at the outset. Hydroquinone above 4% is a course, not a standing order.
- Stop immediately and seek advice if the treated skin darkens, greys or takes on a bluish cast rather than lightening.
- Do not use it if there is any chance you are pregnant.

### Where we stand

This is the lowest score in the register and the first product we are advising against. The reasoning is narrow and specific: not that treating this is wrong, not that hydroquinone is unusable, and not that every formula behind this page is bad — Tender is good and Delight is reasonable.

The objection is that a single page, with no published concentrations and no site-specific dosing, can dispense hydroquinone at three times the conventional prescription strength for application to the most permeable skin on the human body, under natural occlusion, indefinitely — and that it does so for an appearance which, at these exact sites, is one of medicine's better-known signs of insulin resistance.

Every one of those is fixable, and none of the fixes is a reformulation. Publish the four formulas. Make Tender the default. Add site-specific dosing. Add one screening question about onset and symmetry. Do that and this becomes a defensible product on a page we would score very differently.

## Where to buy

| Retailer | Price | Link | Note | Commission-bearing |
| --- | --- | --- | --- | --- |
| Musely | $36 / mo | https://www.musely.com/privatecream?utm_source=30plusskin&utm_medium=affiliate&utm_campaign=review&utm_content=musely-the-private-cream&utm_term=markdown | Prescription. Consultation required. Four formulas; you do not choose. | yes — affiliate link |

We do not recommend this as sold. If you proceed, read the absorption and the acanthosis nigricans sections above first, and ask specifically about the Tender formula.

## Sources

- [Musely — The Private Cream product page](https://www.musely.com/privatecream) — Price, marketed application sites including genital and perianal, the three ingredients named without concentrations, the 71% self-report figure.
- [Musely Help Centre — formulas for The Private Cream](https://support.musely.com/hc/en-us/articles/1500001687902-What-are-the-formulas-for-The-Private-Cream) — Source of the four formulas: Desire HQ 12%, Bliss HQ 6%, Delight HQ 3%, Tender TXA 6% — all with niacinamide 2%.
- [Feldmann & Maibach — regional variation in percutaneous penetration in man](https://www.tandfonline.com/doi/abs/10.1080/00039896.1971.10665987) — The foundational regional absorption dataset: scrotum approximately 42× forearm, axilla four- to sevenfold.
- [Regional variation in percutaneous absorption — systematic review of in vitro human models](https://pubmed.ncbi.nlm.nih.gov/35094673/) — Modern corroboration of large regional differences in percutaneous absorption.
- [Acanthosis Nigricans — StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK431057/) — Presentation at axilla, neck and groin; association with obesity and insulin resistance.
- [Insulin resistance in acanthosis nigricans (EADV)](https://eadv.org/2023/10/03/insulin-resistance-in-acanthosis-nigricans/) — Acanthosis nigricans as a clinical marker of hyperinsulinaemia and metabolic syndrome.
- [Ishack et al. — exogenous ochronosis associated with hydroquinone: a systematic review](https://onlinelibrary.wiley.com/doi/10.1111/ijd.15878) — Reported cases cluster above 4% and with prolonged use over large areas.

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_EVERY FIGURE RESOLVES TO A RECORD. NO NUMBER ON THIS SITE IS AUTHORED BY US._